The Concinnity Company, developer of smarter software for clinical trial oversight, partners with Neuren Pharmaceuticals (ASX: NEU) to provide next level clinical trial oversight management
NASHVILLE – February 10, 2022 – We are extremely happy to be Neuren’s partner in improving the lives of people with neurodevelopmental disabilities” said Nancy Falls, Concinnity Company CEO. Neuren Pharmaceuticals (ASX: NEU) is developing new therapies…